BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 20014314)

  • 1. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.
    Arora VK; Sarungbam J; Bhatia A; Singh N; Agrawal V; Aggarwal S
    Diagn Cytopathol; 2010 Nov; 38(11):788-90. PubMed ID: 20014314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM; Kiemeney LA; Witjes JA
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
    Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
    Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
    Casella R; Huber P; Blöchlinger A; Stoffel F; Dalquen P; Gasser TC; Lehmann K
    J Urol; 2000 Dec; 164(6):1926-8. PubMed ID: 11061883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
    Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
    Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of usefulness of urinary nuclear matrix protein 22 (NMP22) in the detection of urothelial transitional cell carcinoma].
    Miyoshi Y; Matsuzaki J; Miura T
    Hinyokika Kiyo; 2001 Jun; 47(6):379-83. PubMed ID: 11496392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
    Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H
    Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
    Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
    Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
    O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
    J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Urinary tumor marker for urothelial cancer].
    Ohtani M; Iwasaki A; Shiraiwa H
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H; Kor K; Djalali M
    Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
    Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
    Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical efficacy of Bladder Chek NMP22 in urothelial cancer].
    Yokoyama T; Sekigawa R; Hayashi T; Horita S; Kanamuro T; Nonami Y; Sawada T; Nishikawa T; Kobayashi M; Yamaguchi Y; Ishida H; Goya N; Nakazawa H; Toma H
    Rinsho Byori; 2004 Mar; 52(3):199-203. PubMed ID: 15137316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22.
    Raina R; Pahlajani G; Ponsky LE; Agarwal A; Zippe CD
    BJU Int; 2008 Aug; 102(3):297-300. PubMed ID: 18702780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.